-
Kenya's economy faces climate change risks: World Bank
-
Meta partners with news outlets to expand AI content
-
Penguins queue in Paris zoo for their bird flu jabs
-
Sri Lanka issues fresh landslide warnings as toll nears 500
-
Stocks, dollar rise before key US inflation data
-
After wins abroad, Syria leader must gain trust at home
-
Markets rise ahead of US data, expected Fed rate cut
-
German factory orders rise more than expected
-
Flooding kills two as Vietnam hit by dozens of landslides
-
Italy to open Europe's first marine sanctuary for dolphins
-
Hong Kong university suspends student union after calls for fire justice
-
Asian markets rise ahead of US data, expected Fed rate cut
-
Georgia's street dogs stir affection, fear, national debate
-
Pandas and ping-pong: Macron ending China visit on lighter note
-
TikTok to comply with 'upsetting' Australian under-16 ban
-
Pentagon endorses Australia submarine pact
-
Softbank's Son says super AI could make humans like fish, win Nobel Prize
-
OpenAI strikes deal on US$4.6 bn AI centre in Australia
-
Rains hamper Sri Lanka cleanup after deadly floods
-
Unchecked mining waste taints DR Congo communities
-
Asian markets mixed ahead of US data, expected Fed rate cut
-
French almond makers revive traditions to counter US dominance
-
Aid cuts causing 'tragic' rise in child deaths, Bill Gates tells AFP
-
Abortion in Afghanistan: 'My mother crushed my stomach with a stone'
-
How to Manage ESG Data Efficiently
-
Mixed day for US equities as Japan's Nikkei rallies
-
To counter climate denial, UN scientists must be 'clear' about human role: IPCC chief
-
Facebook 'supreme court' admits 'frustrations' in 5 years of work
-
South Africa says wants equal treatment, after US G20 exclusion
-
One in three French Muslims say suffer discrimination: report
-
Microsoft faces complaint in EU over Israeli surveillance data
-
Milan-Cortina organisers rush to ready venues as Olympic flame arrives in Italy
-
Truth commission urges Finland to rectify Sami injustices
-
Stocks rise eyeing series of US rate cuts
-
Italy sweatshop probe snares more luxury brands
-
EU hits Meta with antitrust probe over WhatsApp AI features
-
Russia's Putin heads to India for defence, trade talks
-
South Africa telecoms giant Vodacom to take control of Kenya's Safaricom
-
Markets mixed as traders struggle to hold Fed cut rally
-
Asian markets mixed as traders struggle to hold Fed cut rally
-
In Turkey, ancient carved faces shed new light on Neolithic society
-
Asian markets stumble as traders struggle to hold Fed cut rally
-
Nintendo launches long-awaited 'Metroid Prime 4' sci-fi blaster
-
Trump scraps Biden's fuel-economy standards, sparking climate outcry
-
US stocks rise as weak jobs data boosts rate cut odds
-
Poor hiring data points to US economic weakness
-
Germany to host 2029 women's Euros
-
Satellite surge threatens space telescopes, astronomers warn
-
Greek govt warns farmers not to escalate subsidy protest
-
EU agrees deal to ban Russian gas by end of 2027
Disgraced surgeon on trial in Sweden over windpipe transplants
An Italian doctor who made headlines for pioneering windpipe surgery went on trial in Sweden on Wednesday, charged with assault for performing the experimental procedure.
Paolo Macchiarini won praise in 2011 after claiming to have performed the world's first synthetic trachea transplants using stem cells while he was a surgeon at Stockholm's Karolinska Institute.
The procedure was hailed as a breakthrough in regenerative medicine.
But allegations soon emerged that the risky procedure had been carried out on at least one person who had not been critically ill at the time of the operation.
The 63-year-old appeared in court in a blue suit Wednesday, where he listened to translated audio as prosecutors listed the charges of "aggravated assault" against three patients.
- 'Disregard for science' -
The Karolinska Institute has confirmed that the three individuals have since died, but did not directly link the deaths to the operations.
"Macchiarini has carried out the surgery with complete disregard for science and tried experience," prosecutor Karin Lundstrom-Kron told the court.
As prosecutors presented their case they referenced both external and internal reviews of the case, including one published in 2016 by physician Kjell Asplund, who argued that Macchiarini should never have been employed by Karolinska in the first place.
"It is clear that this method has not worked," prosecutor Jim Westerberg said, adding that Macchiarini had embellished the benefits of the procedure.
Macchiarini, who took notes without showing much emotion, has maintained the operations constituted treatments and not experiments, and denied being criminally responsible.
"He contends that he has performed health care, cured and helped," Macchiarini's lawyer Bjorn Hurtig told AFP during a recess.
The prosecution's presentation of evidence is expected to continue over several days so the defence will likely not be able to present its side until next week.
But Hurtig said they had "high hopes" they would be able to counter the prosecution's evidence.
"There are quite a lot of gaps in that evidence and there is a lot of evidence that we argue are favourable to our view of things," he said.
- Downplayed risks -
In 2013, the Karolinska hospital suspended all transplants and refused to extend Macchiarini's contract as a surgeon.
A year later, several surgeons at the hospital filed a complaint alleging that Macchiarini had downplayed the risks of the procedure.
Macchiarini carried out three surgeries at Karolinska University Hospital in 2011 and 2012, using an artificial windpipe made of plastic and coating it with the patient's own stem cells.
Together with his colleagues, he performed a total of eight such transplants between 2011 and 2014, the five others taking place in Russia.
An external review in 2015 found Macchiarini guilty of research misconduct, but despite sacking him, the Karolinska Institute repeatedly defended him until 2018, when it found him and several other researchers guilty.
The university's principal stepped down over the scandal, as well as a number of other people.
Medical journal The Lancet in 2018 retracted two papers authored by Macchiarini.
The trial, held in the Solna district court near the Karolinska Institute, is scheduled to take place over 13 days.
Ng.A.Adebayo--CPN